Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications; alternating positions

September 18, 2017 8:03am

Are we always expecting the sector to go down? The answer relates to what can be absorbed.

Preview RMi's morning call. You’d be reading this if you were a SUBSCRIBER!

Pre-open indications: 3 BUYs and 3 SELLs

Out and about: Pluristem (PSTI) The pre-market indication is a positive +0.29% or +21.64% after PSTI was awarded fast-track designation by the U.S. FDA for a treatment for Critical Limb Ischemia, or CLI. The FDA was weighing in on a late-stage trial of PLX-PAD cells for CLI in patients who are not eligible for revascularization.

If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know when to get in and out or get back in again! It’s called premium content for a reason: I reporting the truth in this sector!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 4 min ago
RegMed Investors (RMi) Closing Bell: a tough week; tied to cross-currents of geopolitical conflicts and recurring inflation

14 hours 47 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.